RFK Jr. stated he "couldn't be more pleased" to announce that COVID-19 vaccination among healthy children and pregnant women has been removed from CDC's immunization schedule. "I couldn't be more ...

Our editor-in-chief Tina Tan, MD, reacts to a new FDA COVID-19 framework that will limit eligibility for seasonal vaccination in pediatrics. "Unfortunately, that basically does eliminate access of ...

The approved indication now includes children down to 6 weeks of age to protect against invasive meningococcal disease via serogroups A, C, W, and Y. On May 23, 2025, the FDA approved an expanded ...

Colleen Sloan, PA-C, RDN, highlights what she is seeing in practice related to screen time, devices, and social media and impacts on nutrition. Colleen Sloan, PA-C, RDN, registered dietitian in ...

Delandistrogene moxeparvovec-rokl (ELEVIDYS) showed significant motor function improvements in 8- to 9-year-old Duchenne muscular dystrophy patients in part 2 of the phase 3 EMBARK study. In part 2 of ...

Most videos on TikTok regarding hormonal contraception were misleading, according to a study presented at the 2025 ACOG Annual Clinical and Scientific Meeting. Millions turn to TikTok for health ...

Severe RSV disease in 2022–2023 was most likely to occur in infants under 6 months and older children with pulmonary or neurologic conditions. Infants younger than 6 months and premature babies had ...

In the first season following the introduction of a new maternal respiratory syncytial virus (RSV) vaccine, data presented at the 2025 American College of Obstetricians and Gynecologists (ACOG) Annual ...

Safety, phosphate level gains, and immunogenicity data offer encouraging signals in the pivotal trial. Inozyme Pharma has announced interim results from its phase 3 ENERGY 3 trial evaluating INZ-701 ...

“These findings provide evidence that social media may be contributing to the development of depressive symptoms,” said Jason M. Nagata, MD, MSc. A new longitudinal study published in JAMA Network ...

Somapacitan was non-inferior and had a similar safety profile and clinical outcomes compared to once-daily somatropin in improving yearly growth rates. Once-weekly somapacitan matched or outperformed ...

NVX-CoV2705 is indicated for individuals aged 12 to 64 years with an underlying condition that poses high risk for severe COVID-19 outcomes. Approval was based on phase 3 trials showing strong ...